Substrate
Topic

pharmaceutical-revenue

1 stories related to this topic, newest first.

ImmunityBio Reports Record Q1 Revenue Tripling Year-Over-Year Driven by Anktivainsidermonkey.com
finance25 days ago

ImmunityBio Reports Record Q1 Revenue Tripling Year-Over-Year Driven by Anktiva

Zoetis reported lower-than-expected first-quarter 2026 results driven by U.S. headwinds and lowered its financial guidance. Separately, ImmunityBio shares dropped 11.46 percent despite record revenue growth from its cancer drug Anktiva.

seekingalpha.com
Benzinga
2 sources